Nimotuzumab in pediatric glioma (Q37630569)

21 August 2017

1 reference

title

Nimotuzumab in pediatric glioma (English)

1 reference

21 August 2017

2

Eric Bouffet

1 reference

21 August 2017

3

Ute Bartels

1 reference

21 August 2017

Catherine Lam

1

1 reference

21 August 2017

language of work or name

English

0 references

publication date

1 November 2009

1 reference

21 August 2017

1 reference

21 August 2017

volume

5

1 reference

21 August 2017

issue

9

1 reference

21 August 2017

page(s)

1349-1361

1 reference

Epidemiology of central nervous system tumors in childhood and adolescence based on the new WHO classification

21 August 2017

cites work

1 reference

Phase II study of high-dose chemotherapy before radiation in children with newly diagnosed high-grade astrocytoma: final analysis of Children's Cancer Group Study 9933.

21 January 2018

1 reference

High-grade astrocytomas in children: radiologically complete resection is associated with an excellent long-term prognosis

21 January 2018

1 reference

The influence of central review on outcome associations in childhood malignant gliomas: results from the CCG-945 experience

21 January 2018

1 reference

The effectiveness of chemotherapy for treatment of high grade astrocytoma in children: results of a randomized trial. A report from the Childrens Cancer Study Group

21 January 2018

1 reference

Outcome of children with centrally reviewed low-grade gliomas treated with chemotherapy with or without radiotherapy on Children's Cancer Group high-grade glioma study CCG-945.

21 January 2018

1 reference

MGMT gene silencing and benefit from temozolomide in glioblastoma

21 January 2018

1 reference

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

21 January 2018

1 reference

Optimal role of temozolomide in the treatment of malignant gliomas.

21 January 2018

1 reference

Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group

21 January 2018

1 reference

Role of temozolomide in pediatric brain tumors

21 January 2018

1 reference

Trends in reported incidence of primary malignant brain tumors in children in the United States

21 January 2018

1 reference

Diffuse brainstem glioma in children: critical review of clinical trials

21 January 2018

1 reference

Radiotherapy followed by high dose busulfan and thiotepa: a prospective assessment of high dose chemotherapy in children with diffuse pontine gliomas.

21 January 2018

1 reference

There is no role for hyperfractionated radiotherapy in the management of children with newly diagnosed diffuse intrinsic brainstem tumors: results of a Pediatric Oncology Group phase III trial comparing conventional vs. hyperfractionated radiotherap

21 January 2018

1 reference

Outcome of children with brain stem gliomas after treatment with 7800 cGy of hyperfractionated radiotherapy. A Childrens Cancer Group Phase I/II Trial.

21 January 2018

1 reference

Treatment of children with diffuse intrinsic brain stem glioma with radiotherapy, vincristine and oral VP-16: a Children's Oncology Group phase II study

21 January 2018

1 reference

Brain stem gliomas: a classification system based on magnetic resonance imaging

21 January 2018

1 reference

Advances toward an understanding of brainstem gliomas

21 January 2018

1 reference

Radiologic classification of brain stem tumors: correlation of magnetic resonance imaging appearance with clinical outcome

21 January 2018

1 reference

Why the epidermal growth factor receptor? The rationale for cancer therapy

21 January 2018

1 reference

Current situation of Panitumumab, Matuzumab, Nimotuzumab and Zalutumumab

21 January 2018

1 reference

Epidermal growth factor receptor inhibitors in neuro-oncology: hopes and disappointments

21 January 2018

1 reference

Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients.

21 January 2018

1 reference

Tyrosine kinase expression in pediatric high grade astrocytoma

21 January 2018

1 reference

Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma

21 January 2018

1 reference

Epithelial Growth Factor Receptor Inhibitors for treatment of recurrent or progressive high grade glioma: an exploratory study.

21 January 2018

1 reference

Lessons learned in the development of targeted therapy for malignant gliomas.

21 January 2018

1 reference

Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.

21 January 2018

1 reference

Phase II trial of gefitinib in recurrent glioblastoma

21 January 2018

1 reference

Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).

21 January 2018

1 reference

Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034.

21 January 2018

1 reference

Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib

21 January 2018

1 reference

EGFR tyrosine kinase domain mutations in human gliomas

21 January 2018

1 reference

Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain

21 January 2018

1 reference

Detection of humoral response in patients with glioblastoma receiving EGFRvIII-KLH vaccines.

21 January 2018

1 reference

Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma

21 January 2018

1 reference

Protein expression of platelet-derived growth factor receptor correlates with malignant histology and PTEN with survival in childhood gliomas

21 January 2018

1 reference

Biology of interactions: antiepidermal growth factor receptor agents

21 January 2018

1 reference

Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients

21 January 2018

1 reference

Radioiodinated (I-125) monoclonal antibody 425 in the treatment of high grade glioma patients: ten-year synopsis of a novel treatment.

21 January 2018

1 reference

Phase I and pharmacokinetic studies of erlotinib administered concurrently with radiotherapy for children, adolescents, and young adults with high-grade glioma.

21 January 2018

1 reference

Targeting the epidermal growth factor receptor in high-grade astrocytomas

21 January 2018

1 reference

Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: a Pediatric Brain Tumor Consortium report

21 January 2018

1 reference

Compassionate use of bevacizumab (Avastin) in children and young adults with refractory or recurrent solid tumors

21 January 2018

1 reference

Targeting EGF-receptor-signalling in squamous cell carcinomas of the head and neck.

21 January 2018

1 reference

Humanization of a mouse monoclonal antibody that blocks the epidermal growth factor receptor: recovery of antagonistic activity

21 January 2018

1 reference

Pharmacological evaluation of humanized anti-epidermal growth factor receptor, monoclonal antibody h-R3, in patients with advanced epithelial-derived cancer

21 January 2018

1 reference

Humanized versus murine anti-human epidermal growth factor receptor monoclonal antibodies for immunoscintigraphic studies

21 January 2018

1 reference

Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer

21 January 2018

1 reference

Enhancement of the antitumor activity of ionising radiation by nimotuzumab, a humanised monoclonal antibody to the epidermal growth factor receptor, in non-small cell lung cancer cell lines of differing epidermal growth factor receptor status

21 January 2018

1 reference

Immunohistochemical recognition of the epidermal growth factor receptor by the h-R3 antibody in the skin of experimental animals

21 January 2018

1 reference

Biodistribution and internal dosimetry of the 188Re-labelled humanized monoclonal antibody anti-epidemal growth factor receptor, nimotuzumab, in the locoregional treatment of malignant gliomas.

21 January 2018

1 reference

Phase I clinical evaluation of a neutralizing monoclonal antibody against epidermal growth factor receptor

21 January 2018

1 reference

Phase I clinical evaluation of a neutralizing monoclonal antibody against epidermal growth factor receptor in advanced brain tumor patients: preliminary study

21 January 2018

1 reference

Motexafin gadolinium modulates levels of phosphorylated Akt and synergizes with inhibitors of Akt phosphorylation

21 January 2018

1 reference

Pediatric phase I and pharmacokinetic study of erlotinib followed by the combination of erlotinib and temozolomide: a Children's Oncology Group Phase I Consortium Study

21 January 2018

1 reference

Phase I and pharmacokinetic study of gefitinib in children with refractory solid tumors: a Children's Oncology Group Study

21 January 2018

1 reference

A phase II study of the farnesyl transferase inhibitor, tipifarnib, in children with recurrent or progressive high-grade glioma, medulloblastoma/primitive neuroectodermal tumor, or brainstem glioma: a Children's Oncology Group study

21 January 2018

1 reference

Phase I trial of tipifarnib in children with newly diagnosed intrinsic diffuse brainstem glioma

21 January 2018

1 reference

Efficacy of Letrozole Extended Adjuvant Therapy According to Estrogen Receptor and Progesterone Receptor Status of the Primary Tumor: National Cancer Institute of Canada Clinical Trials Group MA.17

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.2217/FON.09.119

1 reference

release_3wp2siaxyncwbhmvzrzrh7uryi

21 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/3wp2siaxyncwbhmvzrzrh7uryi

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference